Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds
Biktarvy Settlement Totals $1.25bn Up Front, 3% US Bictegravir Royalty
Executive Summary
The company said in its fourth quarter earnings report that it would not seek accelerated approval for the drug, while it also settled an HIV drug-related intellectual property lawsuit with GSK/ViiV.
You may also be interested in...
Gilead’s Magrolimab Mostly Back On Track As FDA Lifts AML, MDS Holds
The clinical holds, initially announced in January, raised concerns about the company losing its edge in CD47-targeting drugs. Partial holds on the DLBCL and myeloma programs remain in place.
Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma
Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.
Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers
Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.